In this study we demonstrate that ebselen reduces potently the enzymatic activity of SHIP2 in cultured myotubes and hepatoma cells, while the known SHIP2 inhibitors, metformin and AS1949490, inhibit SHIP2 only in myotubes 17. The gene discussed is INPPL1; the disease is hepatocellular carcinoma.